HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Focal membranoproliferative glomerulonephritis — Clinical Guidelines

Overview

Focal membranoproliferative glomerulonephritis (MPGN) is characterized by immune complex deposition and C3 complement activation in the glomeruli, leading to progressive renal damage and often irreversible kidney dysfunction 1.

Diagnosis

Renal biopsy essential for definitive diagnosis, identifying characteristic features such as mesangial cell proliferation and double contours of the glomerular basement membrane 1.

Presence of glomerular C3 deposits aids in distinguishing MPGN from other glomerulopathies 1.

Serum complement levels (C3) can be hypocomplementemic in some cases, though not universally 1 11.

Elevated serum IgG3 levels observed in patients with chronic MPGN 11.

Management

First-line treatments: Corticosteroids and immunosuppressive agents (e.g., cyclophosphamide, mycophenolate mofetil) are commonly used, though efficacy varies 1.

Adjunctive therapies: Plasma exchange may be considered in severe cases with significant proteinuria or rapidly declining renal function 1.

Novel therapies: Pegcetacoplan, a C3 inhibitor, shows promise in clinical trials for C3 glomerulopathy and primary immune-complex MPGN, though specific dosing and long-term outcomes are still under investigation 1.

Special Populations

Pediatrics: MPGN can present early in childhood, even as young as 15 months 8. Transition management is crucial as these patients often require lifelong care 2.

Comorbidities: Patients with genetic syndromes like Prader-Willi syndrome may have increased susceptibility to renal disease 6.

Specific associations: MPGN can be linked with conditions such as partial lipodystrophy and certain genetic mutations affecting Factor H 10 3.

Key Recommendations

Renal biopsy is essential for diagnosing MPGN and differentiating it from other glomerulopathies (Evidence: Strong 1).

Corticosteroids and immunosuppressive agents should be considered as first-line treatments, though response varies (Evidence: Moderate 1).

Monitor serum complement levels (C3) and IgG3 levels for prognostic insights in MPGN patients (Evidence: Moderate 1 11).

Consider novel therapies like pegcetacoplan in severe cases based on emerging trial data (Evidence: Weak 1).

Special attention to transition care is necessary for pediatric patients with MPGN due to their need for long-term management (Evidence: Expert opinion 2).

References

1 Fakhouri F, Bomback AS, Ariceta G, Delmas Y, Dixon BP, Gale DP et al.. Trial of Pegcetacoplan in C3 Glomerulopathy and Immune-Complex MPGN. The New England journal of medicine 2025. link 2 Iitaka K, Motoyama O, Nakamura S, Koshino H, Sakai T. Transition of children with membranoproliferative glomerulonephritis to adolescence and adulthood. Clinical and experimental nephrology 2008. link 3 Goodship TH. Factor H genotype-phenotype correlations: lessons from aHUS, MPGN II, and AMD. Kidney international 2006. link 4 Salazar-Exaire D, Rodríguez A, Galindo-Rujana ME, Briones JC, Arenas-Osuna J, Rocha LM et al.. Membranoproliferative glomerulonephritis associated with a mixed-cell germinal ovary tumor. American journal of nephrology 2001. link 5 Gupta IR, Tsai CH, Siegel-Bartelt J, Thorner P, Balfe JW. Cutaneous telangiectasias, sparse hair, and type I membranoproliferative glomerulonephritis. Pediatric nephrology (Berlin, Germany) 1999. link 6 Robson WL, Leung AK. Membranoproliferative glomerulonephritis in a child with Prader-Willi syndrome. American journal of medical genetics 1992. link 7 Leys A, Proesmans W, Van Damme-Lombaerts R, Van Damme B. Specific eye fundus lesions in type II membranoproliferative glomerulonephritis. Pediatric nephrology (Berlin, Germany) 1991. link 8 James S, Neiberger R, Donnelly W, Iravani A, Fennell RS, Richard G. Membranoproliferative glomerulonephritis in a fifteen-month-old boy. Child nephrology and urology 1990. link 9 Sherwood MC, Pincott JR, Goodwin FJ, Dillon MJ. Dominantly inherited glomerulonephritis and an unusual skin disease. Archives of disease in childhood 1987. link 10 Chartier S, Buzzanga JB, Paquin F. Partial lipodystrophy associated with a type 3 form of membranoproliferative glomerulonephritis. Journal of the American Academy of Dermatology 1987. link80062-2) 11 Thompson RA. IgG3 levels in patients with chronic membranoproliferative glomerulonephritis. British medical journal 1972. link

Focal membranoproliferative glomerulonephritis